1. Home
  2. LU vs ANIP Comparison

LU vs ANIP Comparison

Compare LU & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lufax Holding Ltd each representing two (2)

LU

Lufax Holding Ltd each representing two (2)

HOLD

Current Price

$1.91

Market Cap

2.3B

Sector

Finance

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$74.81

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LU
ANIP
Founded
2005
2001
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.7B
IPO Year
2020
1999

Fundamental Metrics

Financial Performance
Metric
LU
ANIP
Price
$1.91
$74.81
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$110.00
AVG Volume (30 Days)
1.7M
326.6K
Earning Date
03-23-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
419.23
EPS
N/A
3.32
Revenue
N/A
$206,547,000.00
Revenue This Year
N/A
$23.05
Revenue Next Year
$22.52
$14.08
P/E Ratio
N/A
$22.31
Revenue Growth
N/A
2.47
52 Week Low
$1.73
$56.71
52 Week High
$4.57
$99.50

Technical Indicators

Market Signals
Indicator
LU
ANIP
Relative Strength Index (RSI) 26.62 48.22
Support Level N/A $71.29
Resistance Level $2.77 $77.47
Average True Range (ATR) 0.10 2.29
MACD -0.04 0.27
Stochastic Oscillator 26.21 63.66

Price Performance

Historical Comparison
LU
ANIP

About LU Lufax Holding Ltd each representing two (2)

Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Share on Social Networks: